Frazier Life Sciences
3 rounds tracked since 8 January 2026.
- Rounds
- 3
- Led
- 2
- Capital in these rounds
- $572M
Sectors
Countries
Rounds
- Crystalys TherapeuticsLeadBiopharmaceutical company advancing dotinurad through global Phase 3 development for gout treatment. $130MSeries B · 22 Jul
- Sidewinder TherapeuticsLeadDevelops precision bispecific antibody-drug conjugates for cancer treatment. $137MSeries B · 8 Apr
- Parabilis MedicinesDevelops oncology therapies, including FOG-001 (zolucatetide), using its Helicon platform. $305M8 Jan
Often invests with
The Daily Raise
The day's rounds in your inbox each morning.
Subscribe to The Daily Raise